Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
KALA BIO Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
KALA
Nasdaq
2834
https://www.kalarx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for KALA BIO Inc
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 29th, 2024 12:00 pm
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
- Feb 26th, 2024 1:00 pm
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 1:00 pm
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan 19th, 2024 9:01 pm
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 1:00 pm
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:00 pm
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
- Aug 15th, 2023 2:20 pm
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 4th, 2023 12:00 pm
KALA BIO to Participate in Upcoming Investor Conferences in August
- Aug 2nd, 2023 8:01 pm
Kala Pharmaceuticals Announces Name Change to KALA BIO
- Aug 2nd, 2023 12:00 pm
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jul 19th, 2023 8:01 pm
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
- Jun 2nd, 2023 12:00 pm
10 Best Stocks to Buy for a Quick Return
- May 11th, 2023 4:20 pm
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
- May 9th, 2023 12:00 pm
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
- Apr 28th, 2023 12:00 pm
Scroll